dm+d

Unassigned

New Medicines

DB109Alzheimer's disease - mild to moderate

Information

DB109
New molecular entity
Denovo Biopharma
Denovo Biopharma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Selective 5-HT6 antagonist
Alzheimers disease is the most common form of dementia, accounting for 50%-60% of all cases. The prevalence of dementia is below 1% in individuals aged 60-64 years, but shows an almost exponential increase with age, so that in people aged 85 years or older the prevalence is between 24% and 33% in the Western world.
Alzheimer's disease - mild to moderate
Oral